Introduction: Elderly patients have higher rates of morbidity and mortality during hospitalizations, diagnostic and surgical procedures. In order to improve the quality of care for the elderly, the APOIO (Preoperative Assessment of Elderly and Care Guidance) protocol was created, a tool to measure the risks of surgical complications. Objective: To evaluate the impact of APOIO on several outcomes, in order to validate it as a useful vehicle in the prevention of perioperative complications in elderly patients with fractures. Method: Retrospective cross-sectional study through review of 218 medical records of elderly patients hospitalized for fractures, and with surgical indication, having collected data on sex, age, reason for hospitalization, type of fracture, indication or not of surgical treatment, evaluation or not by APOIO, indication or not of ICU in the postoperative period, length of ICU stay, total length of hospitalization, immediate outcome and outcome within 30 days after the operation. Result: It was found that the application of APOIO was associated with a 70% reduction in the chances of death during hospitalization (p=0.040), length of stay in the ICU (p<0.001) and total length of hospital stay (p = 0.010). There was also a trend towards a reduction in the death rate within 30 days of the postoperative period (p = 0.117). Conclusion: The application of the APOIO tool reduces the length of hospitalization, optimizes indication and length of stay in the ICU and, also, reduces the risk of death in elderly people undergoing surgical treatment for fractures.

Introdução: Pacientes idosos apresentam maior morbidade e mortalidade em internamentos hospitalares, procedimentos diagnósticos e cirúrgicos. Buscando melhorar a qualidade assistencial aos idosos foi criado o protocolo APOIO (Avaliação Pré-Operatória de Idosos e Orientação de cuidados), ferramenta para mensurar os riscos de complicações cirúrgicas. Objetivo: Avaliar o impacto do APOIO sobre vários desfechos, a fim de validá-lo como veículo útil na prevenção de complicações perioperatórias em idosos com fraturas. Método: Pesquisa retrospectiva transversal por meio de revisão de 218 prontuários de pacientes idosos internados por fraturas, e com indicação cirúrgica, tendo sido coletados dados sobre sexo, idade, motivo do internamento, tipo de fratura, indicação ou não de tratamento cirúrgico, avaliação ou não pela APOIO, indicação ou não de UTI no pós-operatório, duração do internamento em UTI, duração total do internamento, desfecho imediato e desfecho em 30 dias após a operação. Resultado: Foi constatado que a aplicação do APOIO foi associada à redução de 70% nas chances de óbito durante o internamento (p = 0,040), ao tempo de permanência em UTI (p <0,001) e ao tempo total de internamento hospitalar (p =  0,010). Observou-se ainda tendência à redução na taxa de óbitos em 30 dias do pós-operatório (p = 0,117). Conclusão: A aplicação da ferramenta APOIO reduz tempo de internamento, otimiza indicação e tempo de permanência em UTI e ainda diminui o risco de óbito de idosos submetidos a tratamentos cirúrgicos de fraturas.

Introdução : A obesidade tem sido associada ao aparecimento ou piora de doenças autoimunes. Objetivo : Revisar a presença de autoanticorpos em obesos submetidos à cirurgia bariátrica e verificar a possível alteração deste perfil após o procedimento cirúrgico. Método : Revisão narrativa da literatura efetuada no PubMed e Scielo. A busca utilizou as palavras-chave: “ obesidade, autoimunidade, fator antinuclear, cirurgia bariátrica” . Os critérios de inclusão compreenderam artigos de revisão, estudos experimentais, pesquisas pré-clínicas e clínicas, escritos em português e inglês e disponíveis em texto completo. Resultado : Foram incluídos 63 artigos. Conclusão : Existe alta prevalência de FAN positiva na população obesa e candidata à cirurgia bariátrica que diminui consideravelmente no pós-operatório. O mesmo não pode ser verificado com o fator reumatóide, anticorpos do perfil ENA e anti-ds DNA, anticorpos anticardiolipina IgG e IgM, e anticorpos anti-endomísio. Nenhuma variável clínica ou antropométrica pôde estar ligada à presença de autoanticorpos, salvo níveis de vitamina D que foram significativamente menores nos indivíduos no pré-operatório e FAN positivos.

Introdução : A obesidade tem sido associada ao aparecimento ou agravamento de doenças autoimunes. Objetivo : Rever a presença de autoanticorpos em pacientes obesos submetidos à cirurgia bariátrica e verificar a possível alteração deste perfil após o procedimento cirúrgico. Método : Revisão narrativa da literatura realizada no PubMed e Scielo. A busca utilizou as palavras-chave: “ obesidade, autoimunidade, fator antinuclear, cirurgia bariátrica ”. Os critérios de inclusão compreenderam artigos de revisão, estudos experimentais, pesquisas pré-clínicas e clínicas, escritos em português e inglês e disponíveis em texto completo. Resultado : foram incluídos 63 artigos. Conclusão : Existe alta prevalência de FAN positivo na população obesa e candidata à cirurgia bariátrica, que diminui consideravelmente no pós-operatório. O mesmo não pode ser verificado com fator reumatoide, anticorpos ENA e anti-ds DNA, anticorpos IgG e IgM anticardiolipina e anticorpos antiendomísio. Nenhuma variável clínica ou antropométrica pôde ser associada à presença de autoanticorpos, exceto os níveis de vitamina D, que foram significativamente mais baixos nos indivíduos pré-operatórios e ANA-positivos.

Introduction: Non-melanoma skin neoplasms (basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) form the most common group of all types of neoplasms. Although cancer is not yet being classified as a channelopathy, it has been suggested that pumps and ionic channels contribute to its progression by affecting autophagy, which could become an important therapeutic target in this context. Objective: To evaluate the immunohistochemical expression of IP3R in both skin tumors. Method: Immunohistochemistry was performed on 60 slides of non-melanoma cancer using primary anti-IP3R antibodies, verifying their presence and quantifying Results: For the first time, IP3R immunolocalization was identified in non-melanoma skin neoplasms, being evident above 90% of neoplastic cells was observed in all slides studied, regardless of the histological pattern, invasion and other tumor characteristics. Unlike what was seen in the internal control of normal skin, in which there was immunolocalization of IP3R in basal cell, in tumors, immunohistochemical expression occurred throughout the entire body of the neoplasm. Conclusion: There was immunolocalization of IP3R in tumor cells in both BCC and SCC. It was not possible to establish a correlation between tumor characteristics and IP3R expression, as immunostaining was similar in all analyzed samples. Despite this, IP3R to be associated with the pathophysiology of non-melanoma skin cancer, but its expression does not seem to be associated with tumor aggressiveness.

Introdução: As neoplasias de pele não melanoma (carcinoma basocelular (CBC) e carcinoma espinocelular (CEC) formam o grupo mais comum de todos os tipos de neoplasias. Embora o câncer ainda não esteja sendo pautado como canalopatia, tem sido sugerido que bombas e canais iônicos contribuem para a sua progressão por afetar a autofagia. Proteínas iônicas, em especial as de canais de cálcio, como o receptor da fosfatidil inositol 3 (IP3R) participam de maneira ativa na autofagia por estarem envolvidas na etapa inicial de formação do autofagossomo, podendo se tornar em alvo terapêutico importante neste contexto. Objetivo: Avaliar a expressão imuno histoquímica do IP3R em ambos os tumores de pele. Método: Foi realizada imuno histoquímica em 60 lâminas de câncer não melanoma utilizando anticorpos primários anti-IP3R verificando a sua expressão. Resultados: Pela primeira vez foi identificada a imunolocalização do IP3R em câncer de pele não melanoma, sendo evidente em mais de 90% das células neoplásicas em todas as lâminas estudadas, independentemente do padrão histológico, invasão e demais características tumorais. Diferentemente do visualizado no controle interno de pele normal, no qual houve imunolocalização de IP3R em células basais, nos tumores, a expressão imuno histoquímica ocorreu em todo o corpo da neoplasia. Conclusão: Houve imunolocalização de IP3R em células tumorais tanto em CBC quanto em CEC. Não foi possível estabelecer correlação entre as características tumorais e a expressão de IP3R, pois a imunomarcação apresentou-se de forma similar em todas as amostras analisadas. Apesar disso, IP3R está associado à fisiopatologia do câncer de pele não melanoma, mas a sua expressão não parece estar associada à agressividade tumoral.

Introduction: Non-melanoma skin cancer (NMSC) comprises a group of neoplasms with a high incidence in the world population. It is divided into basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). As it is highly prevalent, understanding the process of oncogenesis and the relationship with ions, proteins and cellular receptors in CPMN can contribute to the evaluation of new therapies. Objective: To understand the oncogenesis process of non-melanoma skin tumors and its relationship with the immunolocalization of IP3R. Method: Integrative literature review with evidence synthesis. The database was PUBMED; the search strategy: “squamous cell carcinoma, AND/OR basal cell carcinoma, AND/OR IP3R, AND/OR immunohistochemistry”. Works published between 2018 and 2023 were considered for review; 40 works were included, fully read and summarized. Results: NMSC is the most common malignant tumor worldwide, with 75-80% being BCC, and up to 25% being SCC. Molecular interactions in general involve a large participation of tumor suppressor molecules, as well as procto-oncogenes. Furthermore, voltage-dependent ion channels control the cytosolic flow of ions, including calcium. The IP3R (phosphatidyl inositol-3 receptor) allows the exit of calcium from the endoplasmic reticulum so that it can be used by the cell for physiological activities such as proliferation, angiogenesis, motility and invasion capacity. Conclusion: The IP3R, due to its immunohistochemical expression characteristics, appears may also be related to the pathophysiology of NMSC.

Introdução: O câncer de pele não melanoma (CPNM) compeende grupo de neoplasias com alta incidência na população mundial. É dividido em carcinoma basocelular (CBC) e de células escamosas (CEC). Por ser de grande prevalência, entender o processo de oncogênese e a relação com íons, proteínas e receptores celulares no CPMN pode contribuir para que novas terapêuticas sejam avaliadas. Objetivo: Entender o processo da oncogênese dos tumores de pele não melanomas e sua relação com a imunolocalização do IP3R. Método: Revisão integrativa da literatura com síntese de evidências. A base de dados foi o PUBMED; a  estratégia de busca: “carcinoma espinocelular, AND/OR carcinoma basocelular, AND/OR IP3R, AND/OR imunoistoquímica”. Foram considerados para revisão os trabalhos publicados entre 2018 e 2023. Foram incluídos 40 trabalhos, integralmente lidos e resumidos. Resultados: CPNMs são os tumores malignos mais comuns em todo o mundo, sendo 75-80% o CBC, e até 25% o CEC. As interações moleculares de forma geral, envolvem grande participação de moléculas supressoras tumorais, assim como de procto-oncogenes. Além disso, canais iônicos voltagem dependente controlam o fluxo citosólico de íons, dentre eles o cálcio. O IP3R (receptor do fosfatidil inositol-3) permite a saída de cálcio do retículo endoplasmático para que seja utilizado pela célula para atividades fisiológias como proliferação, angiogênese, motilidade e capacidade de invasão. Conclusão: O IP3R, pelas características de expressão imunoistoquímica, parece estar relacionado também, à fisiopatologia do CPNM.

Abstract Objectives: to study the side effects and the risk of disease flare after COVID-19 vaccination in Brazilian patients with Systemic Lupus erythematosus (SLE). Materials and methods: this retrospective study investigated a sample of 101 SLE patients for disease activity through the SLE disease activity index (SLEDAI) prior to and after two vaccine doses against SARS-COv-2. Side effects after vaccination were recorded. Results: in this sample, patients receiving two doses of the same vaccine were 10.3% for CoronaVAc; 42.2% for Pfizer, and 47.3% for Astra-Zeneca. Side effects were detected in 76.2% of them, and most of them were mild and moderate; the most common were local pain (62.3%), headache (36.6%), and fatigue (34.6%). The SLEDAI prior to the first dose and after the second dose did not change significantly (p=0.68). Only 4.1% of individuals had increased in SLEDAI ≥than 3 points. Conclusions: vaccination against COVID-19 was well tolerated and safe in SLE patients.

Resumen Objetivos: estudiar los efectos secundarios y el riesgo de exacerbación de la enfermedad después de la vacunación COVID-19 en una muestra de pacientes con lupus eritematoso sistémico (LES). Materiales y métodos: estudio retrospectivo que investigó 101 pacientes con LES. Se determinó la actividad de la enfermedad mediante el Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) antes y después de dos dosis de la vacuna contra el SARS-COv-2. Se registraron los efectos secundarios después de la vacunación. Resultados: los pacientes que recibieron dos dosis de la misma vacuna fueron el 10,3% para CoronaVAc, el 42,2% para Pfizer y el 47,3% para AstraZeneca. Se detectaron efectos secundarios en el 76,2% y la mayoría fue leve/moderado. Los más frecuentes fueron: dolor local (62,3%), cefalea (36,6%) y fatiga (34,6%). El cambio en la mediana del SLEDAI antes de la primera dosis y después de la segunda no fue estadísticamente significativo (p=0,68). Solo el 4,1% de los individuos aumentó el SLEDAI ≥ de 3 puntos. Conclusiones: la vacunación contra la COVID-19 fue bien tolerada y segura en pacientes con LES.

Abstract Background There is a remarkable variability in the frequency of HLA-B27 positivity in patients with spondyloarthritis (SpA), which may be associated with different clinical presentations worldwide. However, there is a lack of data considering ethnicity and sex on the evaluation of the main clinical and prognostic outcomes in mixed-race populations. The aim of this study was to evaluate the frequency of HLA-B27 and its correlation with disease parameters in a large population of patients from the Brazilian Registry of Spondyloarthritis (RBE). Methods The RBE is a multicenter, observational, prospective cohort that enrolled patients with SpA from 46 centers representing all five geographic regions of Brazil. The inclusion criteria were as follow: (1) diagnosis of axSpA by an expert rheumatologist; (2) age ≥18 years; (3) classification according to ASAS axial. The following data were collected via a standardized protocol: demographic data, disease parameters and treatment historical. Results A total of 1096 patients were included, with 73.4% HLA-B27 positivity and a mean age of 44.4 (±13.2) years. Positive HLA-B27 was significantly associated with male sex, earlier age at disease onset and diagnosis, uveitis, and family history of SpA. Conversely, negative HLA-B27 was associated with psoriasis, higher peripheral involvement and disease activity, worse quality of life and mobility. Conclusions Our data showed that HLA-B27 positivity was associated with a classic axSpA pattern quite similar to that of Caucasian axSpA patients around the world. Furthermore, its absence was associated with peripheral manifestations and worse outcomes, suggesting a relevant phenotypic difference in a highly miscegenated population. HLAB27 HLAB HLA B27 B HLA-B2 SpA, , (SpA) worldwide However mixedrace mixed race populations RBE. . (RBE) multicenter observational 4 Brazil follow 1 (1 rheumatologist 2 (2 18 ≥1 years 3 (3 axial protocol historical 109 included 734 73 73.4 444 44 44. ±13.2 132 13 (±13.2 uveitis Conversely psoriasis activity mobility world Furthermore HLAB2 B2 HLA-B (SpA (RBE ( ≥ 10 7 73. ±13. (±13. ±13 (±13 ±1 (±1 ± (±

SUMMARY OBJECTIVE: Patients with rheumatic diseases have an increased risk of infections, especially tuberculosis. In this study, we aimed to recognize the positivity rate of tuberculosis skin test in patients with rheumatoid arthritis and spondyloarthritis and the characteristics of the patients with positive results. METHODS: Retrospective study of tuberculosis skin test results in patients followed from 2004 to 2021 in a single rheumatology unit. Data related to clinical and epidemiological features, along with treatment information referring to the period in which the tuberculosis skin test was performed, were collected from patients’ charts. RESULTS: A total of 723 tests were identified (448 tests in 269 rheumatoid arthritis patients and 275 in 174 spondyloarthritis patients). In the rheumatoid arthritis sample, 31/275 (11.5%) individuals had positive tests, and in the spondyloarthritis, 38/174 (21.8%) had positive tests. In the rheumatoid arthritis sample, patients with positive tuberculosis skin tests used a higher dose of methotrexate than those with negative results (median of 25 mg/week versus median of 20 mg/week respectively; p=0.02). In the spondyloarthritis sample, tuberculosis skin test positivity was associated with alcohol ingestion (13.1% versus 2.9% in users and non-users respectively; p=0.02) and sulfasalazine use (15.7% of positivity in users versus 5% in non-users; p=0.01). CONCLUSION: The tuberculosis skin test-positive prevalence in rheumatoid arthritis was lower than in the spondyloarthritis sample. Patients with rheumatoid arthritis using a higher dosage of methotrexate or with spondyloarthritis using sulfasalazine had more frequency of tuberculosis skin test positivity and should be carefully followed by the attending physician in order to avoid the appearance of full-blown tuberculosis. OBJECTIVE infections METHODS 200 202 unit features performed charts RESULTS 72 448 (44 26 27 17 patients. . patients) sample 31275 31 31/27 11.5% 115 11 5 (11.5% 38174 38 38/17 21.8% 218 21 8 (21.8% 2 mgweek mg week respectively p=0.02. p002 p p=0.02 0 02 13.1% 131 13 1 (13.1 29 9 2.9 nonusers non 15.7% 157 15 7 (15.7 p=0.01. p001 p=0.01 01 p=0.01) CONCLUSION testpositive fullblown full blown 44 (4 3127 3 31/2 11.5 (11.5 3817 38/1 21.8 (21.8 p00 p=0.0 13.1 (13. 2. 15.7 (15. 4 ( 312 31/ 11. (11. 381 38/ 21. (21. p0 p=0. 13. (13 15. (15 (11 (21 p=0 (1 (2 p=

SUMMARY OBJECTIVE: The aim of the study was to compare the epidemiology and clinical profiles of hospital admissions in a single Brazilian Hepatology Unit from the period 2014–2017 to 2019–2022. METHODS: A retrospective analysis of hospital database from the abovementioned periods was done. The study included patients over the age of 18 years who were hospitalized due to complications of diseases such as viral hepatitis, alcoholic disease, nonalcoholic fatty liver disease, and autoimmune liver and drug-induced hepatitis. RESULTS: In both study periods, middle-aged males were predominant and were younger than females. In the first period (2014–2017), hepatitis C (33.5%) was the most prevalent cause of admission, followed by alcoholic liver disease (31.7%). In the second period (2019–2022), nonalcoholic fatty liver disease (38%) and alcoholic liver disease (27.6%) were the most frequent causes of admission. No changes were observed in the proportion of alcoholic liver disease or drug-induced hepatitis in both study periods. The prevalence of viral hepatitis decreased in both genders, with hepatitis C decreasing from 32.4 to 9.7% for males and 35.4 to 10.8% for females, and OR=0.2; 95%CI 0.1–0.3 for both males and females. Similarly, the prevalence of hepatitis B decreased from 19.1 to 8.1% and OR=0.3; 95%CI 0.2–0.5 for males and 8.2 to 3.7% and OR=0.4; 95%CI 0.1–0.9 for females. The prevalence of autoimmune liver diseases increased only in males, from 2.1 to 5.9% and OR=2.9; 95%CI 1.2–6.6. CONCLUSION: Over the past 4 years, there has been a shift in hospital admission profile at a Brazilian Hepatology Unit, with a decrease in viral hepatitis and an increase in autoimmune diseases and nonalcoholic fatty liver disease. Males were more affected at younger ages than females. Furthermore, ascites was the most prevalent cause of complications in both periods analyzed. OBJECTIVE 20142017 2014 2017 2014–201 20192022 2019 2022 2019–2022 METHODS done 1 druginduced drug induced RESULTS middleaged middle aged females 2014–2017, , (2014–2017) 33.5% 335 33 5 (33.5% 31.7%. 317 31.7% . 31 7 (31.7%) 2019–2022, (2019–2022) 38% 38 (38% 27.6% 276 27 6 (27.6% genders 324 32 32. 97 9 9.7 354 35 35. 108 10 8 10.8 OR=0.2 OR02 OR 0 2 95CI CI 95 0103 3 0.1–0. Similarly 191 19 19. 81 8.1 OR=0.3 OR03 0205 0.2–0. 82 8. 37 3.7 OR=0.4 OR04 0109 21 2. 59 5.9 OR=2.9 OR29 1266 1.2–6.6 CONCLUSION Furthermore analyzed 2014201 201 2014–20 2019202 202 2019–202 (2014–2017 33.5 (33.5 31.7 (31.7% (2019–2022 (38 27.6 (27.6 9. 10. OR=0. OR0 010 0.1–0 020 0.2–0 3. 5. OR=2. OR2 126 1.2–6. 201420 20 2014–2 201920 2019–20 (2014–201 33. (33. 31. (31.7 (2019–202 (3 27. (27. OR=0 01 0.1– 02 0.2– OR=2 12 1.2–6 20142 2014– 20192 2019–2 (2014–20 (33 (31. (2019–20 ( (27 OR= 0.1 0.2 1.2– 2019– (2014–2 (31 (2019–2 (2 0. 1.2 (2014– (2019– 1. (2014 (2019 (201 (20

ABSTRACT Background: Low bone mass density (BMD) is an extraintestinal finding in celiac disease (CD). This may result in bone fractures leading to loss in quality of life. Objective: To assess BMD in male CD patients at diagnosis according to the patient’s age. Methods: Descriptive retrospective carried out during the period between 2013 and 2023 in a single office that studied dual-energy X-ray absorptiometry (DXA) results in 28 male patients with a recent diagnosis of CD, divided into three groups: group 1 (age up to 18 years); group 2 (from 19 to 49 years of age) and group 3 (over 50 years of age). Were studied demographic and anthropometric parameters, time delay between symptoms onset and CD diagnosis and fracture occurrence. Results: Celiac patients studied had median age 36.0 years (IQR=16.5-50.7). Among them, 39.3% had osteopenia and 14.3% had osteoporosis. Only 36% of the sample had normal DXA values (group 1 with 37.5%; group 2 with 46% and group 3 with 14.2%). No pathological fracture was observed in this sample. CD diagnosis delay observed had median 1.0 year (IQR=1.0-4.7). When the number of individuals with normal and abnormal DXA results were compared, there was no difference in body mass index, time of diagnosis delay or Marsh classification (P=0.18). Conclusion: Male patients at the time of CD diagnosis showed a high prevalence of low BMD, which was particularly evident in individuals over 50 years of age. Background (BMD CD. . (CD) life Objective patient s Methods 201 202 dualenergy dual energy Xray X ray (DXA groups years) from 4 5 parameters occurrence Results 360 36 0 36. IQR=16.550.7. IQR165507 IQR IQR=16.5 50.7 16 7 (IQR=16.5-50.7) them 393 39 39.3 143 14 14.3 osteoporosis 37.5% 375 37 46 14.2%. 142 14.2% 14.2%) 10 1. IQR=1.04.7. IQR1047 IQR=1.0 4.7 (IQR=1.0-4.7) compared index P=0.18. P018 P P=0.18 (P=0.18) Conclusion (CD 20 550 IQR=16.550.7 IQR16550 IQR165 IQR=16. 507 50. (IQR=16.5-50.7 39. 14. 37.5 14.2 04 IQR=1.04.7 IQR104 IQR10 IQR=1. 47 4. (IQR=1.0-4.7 P01 P=0.1 (P=0.18 55 IQR=16.550. IQR1655 IQR16 IQR=16 (IQR=16.5-50. 37. IQR=1.04. IQR1 IQR=1 (IQR=1.0-4. P0 P=0. (P=0.1 IQR=16.550 (IQR=16.5-50 IQR=1.04 IQR= (IQR=1.0-4 P=0 (P=0. IQR=16.55 (IQR=16.5-5 (IQR=1.0- P= (P=0 (IQR=16.5- (IQR=1.0 (P= (IQR=16.5 (IQR=1. (P (IQR=16. (IQR=1 (IQR=16 (IQR= (IQR

RESUMO Contexto: A baixa densidade de massa óssea (DMO) é um achado extraintestinal na doença celíaca (DC). Isso pode resultar em fraturas ósseas levando à perda de qualidade de vida. Objetivo: Avaliar a DMO em pacientes masculinos com DC no momento do diagnóstico de acordo com a idade do paciente. Métodos: Estudo retrospectivo descritivo realizado no período entre 2013 e 2023 em um único consultório que estudou resultados de “dual-energy X-ray absorptiometry” (DEXA) em 28 pacientes do sexo masculino com diagnóstico recente de DC, divididos em três grupos: grupo 1 (idade até 18 anos); grupo 2 (de 19 a 49 anos) e grupo 3 (acima de 50 anos). Foram estudados parâmetros demográficos e antropométricos, tempo decorrido entre o início dos sintomas e o diagnóstico da DC e ocorrência de fraturas. Resultados: Os pacientes celíacos estudados tinham mediana de idade de 36,0 anos (IIQ=16,5-50,7). Dentre eles, 39,3% apresentavam osteopenia e 14,3% apresentavam osteoporose. Apenas 36% da amostra apresentou valores normais de DEXA (grupo 1 com 37,5%; grupo 2 com 46% e grupo 3 com 14,2%). Nenhuma fratura patológica foi observada nesta amostra. O atraso no diagnóstico da DC observado teve mediana de 1,0 ano (IQR=1,0-4,7). Quando comparado o número de indivíduos com resultados de DEXA normais e alterados, não houve diferença no índice de massa corporal, tempo de atraso no diagnóstico ou classificação de Marsh (P=0,18). Conclusão: Pacientes do sexo masculino no momento do diagnóstico da DC apresentaram alta prevalência de baixa DMO, o que foi particularmente evidente em indivíduos com mais de 50 anos de idade. Contexto (DMO DC. . (DC) vida Objetivo paciente Métodos 201 202 dualenergy dual energy Xray X ray absorptiometry (DEXA grupos 4 acima 5 anos. antropométricos Resultados 360 36 0 36, IIQ=16,550,7. IIQ165507 IIQ IIQ=16,5 50,7 16 7 (IIQ=16,5-50,7) eles 393 39 39,3 143 14 14,3 osteoporose 37,5% 375 37 46 14,2%. 142 14,2% 14,2%) 10 1, IQR=1,04,7. IQR1047 IQR IQR=1,0 4,7 (IQR=1,0-4,7) alterados corporal P=0,18. P018 P P=0,18 (P=0,18) Conclusão (DC 20 550 IIQ=16,550,7 IIQ16550 IIQ165 IIQ=16, 507 50, (IIQ=16,5-50,7 39, 14, 37,5 14,2 04 IQR=1,04,7 IQR104 IQR10 IQR=1, 47 4, (IQR=1,0-4,7 P01 P=0,1 (P=0,18 55 IIQ=16,550, IIQ1655 IIQ16 IIQ=16 (IIQ=16,5-50, 37, IQR=1,04, IQR1 IQR=1 (IQR=1,0-4, P0 P=0, (P=0,1 IIQ=16,550 IIQ1 IIQ=1 (IIQ=16,5-50 IQR=1,04 IQR= (IQR=1,0-4 P=0 (P=0, IIQ=16,55 IIQ= (IIQ=16,5-5 (IQR=1,0- P= (P=0 (IIQ=16,5- (IQR=1,0 (P= (IIQ=16,5 (IQR=1, (P (IIQ=16, (IQR=1 (IIQ=16 (IQR= (IIQ=1 (IQR (IIQ= (IIQ

ABSTRACT BACKGROUND AND OBJECTIVES: The feet may be involved in patients with ankylosing spondylitis (AS), causing pain and walking difficulties. This research aimed to study the involvement of the foot in a sample of Brazilian patients with AS. METHODS: The Brazilian version of the Foot Function Index (FFI-BR) was applied to 103 individuals (57 AS patients and 46 controls). Clinical profiles were obtained in AS patients as well as the measurement of disease activity by the ASDAS (Ankylosing Spondylitis Disease Activity Score)-ESR (erythrocyte sedimentation rate), ASDAS-CRP (C reactive protein) and BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and function by BASFI (Bath Ankylosing spondylitis functional score). RESULTS: Only 19.2% of AS patients did not have any foot complaints and the FFI-BR score presented worse results than the control group (p = 0.02). The "pain" domain of FFI-BR scored highest in AS patients, followed by "disability". There was no association between the results of the FFI-BR and the clinical profile of patients with AS, but there was an association between the score and the disease activity indexes (r = 0.50, p = 0.003 with ASDAS-ESR; r = 0.44, p = 0.005 with ASDAS-CRP; and r = 0.60, p < 0.0001 with BASDAI). The BASFI also showed a positive correlation (r = 0.72; p < 0.0001). CONCLUSION: Pain and disability are common in AS patients and these symptoms are associated with disease activity. OBJECTIVES , (AS) difficulties METHODS FFIBR FFI BR (FFI-BR 10 57 (5 4 controls. controls . controls) ScoreESR Score ESR erythrocyte rate, rate rate) ASDASCRP CRP C protein Bath score. score) RESULTS 192 19 2 19.2 0.02. 002 0.02 0 02 0.02) "pain disability. "disability" 050 50 0.50 0003 003 0.00 ASDASESR ASDAS-ESR 044 44 0.44 0005 005 060 60 0.60 00001 0001 0.000 BASDAI. BASDAI) 0.72 072 72 0.0001. 0.0001) CONCLUSION (AS 1 5 ( 19. 00 0.0 "disability 05 0.5 000 04 0.4 06 6 0.6 0000 0.7 07 7 0.

RESUMO JUSTIFICATIVA E OBJETIVOS: Os pés podem ser acometidos em pacientes com espondilite anquilosante (EA), causando dor e dificuldade de locomoção. O objetivo deste trabalho foi estudar o envolvimento do pé em uma amostra de pacientes brasileiros com EA. MÉTODOS: A versão brasileira do Foot Function Index (FFI-BR) foi aplicada a 103 indivíduos (57 pacientes com EA e 46 controles). O perfil clínico foi obtido para pacientes com EA, bem como a medição da atividade da doença por meio do ASDAS (Ankylosing Spondylitis Disease Activity Score)-ESR. (velocidade de hemossedimentação), ASDAS-CRP (proteína C reativa) e BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) e função pelo BASFI (Bath Ankylosing Spondylitis Functional Score). RESULTADOS: Apenas 19,2% dos pacientes com EA não apresentaram queixas nos pés e o escore FFI-BR apresentou resultados piores do que os do grupo controle (p = 0,02). O domínio "dor" do FFI-BR apresentou a maior pontuação nos pacientes com EA seguido pelo domínio "disfunção". Não se observou associação dos resultados do FFI-BR com o perfil clínico dos pacientes com EA, mas houve associação do escore com os índices de atividade da doença (r = 0,50, p = 0,003 com ASDAS-ESR; r = 0,44, p = 0,005 com ASDAS-CRP; e r = 0,60, p < 0,0001 com BASDAI). O BASFI também apresentou correlação positiva (r = 0,72; p< 0,0001). CONCLUSÃO: Dor e disfunção são comuns em pacientes com EA e estes sintomas se associam com atividade de doença. OBJETIVOS , (EA) locomoção MÉTODOS FFIBR FFI BR (FFI-BR 10 57 (5 4 controles. controles . controles) ScoreESR. ScoreESR Score ESR. ESR Score)-ESR velocidade hemossedimentação, hemossedimentação hemossedimentação) ASDASCRP CRP proteína reativa Bath Score. Score) RESULTADOS 192 19 2 19,2 0,02. 002 0,02 0 02 0,02) "dor disfunção. "disfunção" 050 50 0,50 0003 003 0,00 ASDASESR ASDAS-ESR 044 44 0,44 0005 005 060 60 0,60 00001 0001 0,000 BASDAI. BASDAI) 0,72 072 72 0,0001. 0,0001) CONCLUSÃO (EA 1 5 ( 19, 00 0,0 "disfunção 05 0,5 000 04 0,4 06 6 0,6 0000 0,7 07 7 0,

Abstract Background Nail involvement is frequent in patients with psoriasis (Pso) and psoriatic arthritis (PsA) and there is a relationship between nail involvement and inflammation of the enthesis. The main objective of the present study is to describe the ultrasound findings and clinical characteristics of nails from patients with psoriasis and psoriatic arthritis with and without nail dystrophy. Methods A cross-sectional study including consecutive patients with PsO and PsA was carried out. The study patients were divided into 4 groups, totaling 120 participants. Group 1: patients with psoriasis vulgaris and clinically normal nails; Group 2: patients with psoriasis vulgaris and onychodystrophy; Group 3: patients with psoriatic arthritis and clinically normal nails; Group 4: patients with psoriatic arthritis and onychodystrophy; All patients were submitted to dermatological and rheumatological clinical analysis. Ultrasound examinations was performed by a single examiner, blinded to all clinical data, with ultrasound high resolution, in B-mode or gray-scale (GS), Power Doppler (PD) and Spectral Doppler. Results A significant difference was found between the groups regarding the variable Psoriasis Area and Severity Index (PASI) (p = 0.008) and body surface area (BSA) (p = 0.005), with patients with psoriatic arthritis having lower PASI and BSA compared to patients with only cutaneous psoriasis. A positive relationship was found with the average ultrasound thickness of the nail bed and the Nail Psoriasis Severity Index (NAPSI) in correlation analysis (rho = 0.344). When we grouped patients with psoriasis and psoriatic arthritis, there was no significant difference between the cutaneous psoriasis groups and the psoriatic arthritis groups in terms of nail plate GS (p = 0.442), nail bed PD (p = 0.124). Conclusion Greater nail bed thickness indicates early psoriatic nail disease, as confirmed in our study correlating NAPSI with nail bed thickness. Ultrasonography is a low-cost exam, promising in the evaluation, showing that the ultrasound grayscale is consistent with those who have dystrophic nails, but it can't distinguish psoriasis from psoriatic arthritis, even in those with nail dystrophy. Pso (Pso (PsA enthesis dystrophy crosssectional cross sectional out 12 participants 1 2 onychodystrophy 3 examiner data resolution Bmode B mode gray scale GS, , (GS) (PD (PASI p 0.008 0008 0 008 (BSA 0.005, 0005 0.005 005 0.005) (NAPSI rho 0.344. 0344 0.344 . 344 0.344) 0.442, 0442 0.442 442 0.442) 0.124. 0124 0.124 124 0.124) disease lowcost low cost exam evaluation cant can t (GS 0.00 000 00 034 0.34 34 044 0.44 44 012 0.12 0.0 03 0.3 04 0.4 01 0.1 0.

SUMMARY BACKGROUND: Routine screening for viral infections at blood donation is important to avoid transfusion-transmitted infections. It also offers an opportunity to detect an asymptomatic infection. OBJECTIVE: To study changes in serology positivity for viral infections (B and C hepatitis, HTLV-1/2, and HIV) at blood donation in a blood bank from Southern Brazil, comparing two periods of 5 years: the period from 2013 to 2017 with the period from 2018 to 2022. In addition, data on the donor fidelity rate during the studied period were sought. METHODS: Retrospective study using data from 2013 to 2022 from a single blood center electronic database from Curitiba, Southern Brazil. RESULTS: A significant drop in positive serology for all studied viruses was observed: highest in HIV (OR=0.39; 95% CI=0.27–0.57) and lowest in total anti HBc (0.56; 95 CI=0.50–0.63). Anti HBc serology became more commonly seen in women in the period of 2018–2022 when compared to men. No changes in the distribution of positive serology according to donors’ ages were observed. Loyalty rates had a median of 70%, with the lowest being 60% in 2013, while the highest was 73% in 2018 and 2022. CONCLUSION: A significant reduction in discarded blood bags due to viral serology was observed when the period of 2013–2017 was compared to 2018–2022 on this blood bank; the highest reduction was observed in HIV serology and the lowest in HBc serology, which became more common in women in the second period. High rates of donor fidelity were observed during the period studied. BACKGROUND transfusiontransmitted transfusion transmitted infection OBJECTIVE B hepatitis HTLV1/2, HTLV12 HTLV 1/2, 1 2 HTLV-1/2 Brazil years 201 addition sought METHODS 202 Curitiba RESULTS OR=0.39 OR039 OR 0 39 (OR=0.39 CI=0.27–0.57 CI027057 CI 27 57 0.56 056 56 (0.56 9 CI=0.50–0.63. CI050063 CI=0.50–0.63 . 50 63 CI=0.50–0.63) 20182022 2018–202 men donors 70 70% 60 73 CONCLUSION 20132017 2013–201 HTLV1 HTLV1/2 12 1/2 HTLV-1/ 20 OR=0.3 OR03 3 (OR=0.3 CI=0.27–0.5 CI02705 0.5 05 (0.5 CI05006 CI=0.50–0.6 6 2018202 2018–20 7 2013201 2013–20 HTLV1/ 1/ HTLV-1 OR=0. OR0 (OR=0. CI=0.27–0. CI0270 0. (0. CI0500 CI=0.50–0. 201820 2018–2 201320 2013–2 HTLV- OR=0 (OR=0 CI=0.27–0 CI027 (0 CI050 CI=0.50–0 20182 2018– 20132 2013– OR= (OR= CI=0.27– CI02 ( CI05 CI=0.50– (OR CI=0.27 CI0 CI=0.50 CI=0.2 CI=0.5 CI=0. CI=0 CI=

Introduction: The Charlson comorbidities index (CCI) assesses a person's chances of survival over the next 10 years. In systemic lupus erythematosus (SLE), multiple comorbidities and complications affect patient survival. Objetive: Analize the variables that influence the CCI of a group of females with SLE. Methods: Retrospective study of medical records of 100 lupus patients for CCI, clinical, epidemiological and serological variables. Results: No epidemiological variable interfered in CCI. Regarding clinical manifestations, patients with glomerulonephritis had a worse CCI than those without (p&lt;0.0001) and those with central nervous system manifestations had a tendency to worse CCI (p=0.09). Patients with anti-Ro antibodies (p=0.02) and rheumatoid factor or RF (p=0.002) were associated with a lower CCI. Conclusions: The presence of glomerulonephritis is associated with lower survival and of the anti-Ro and RF antibodies with longer survival in SLE.

Introdução : O índice de comorbidades de Charlson (ICC) avalia as chances de sobrevivência de uma pessoa nos próximos 10 anos. No lúpus eritematoso sistêmico (LES) múltiplas comorbidades e complicações afetam a sobrevida. Objetivo : Verificar as variáveis ​​que influenciam no ICC de um grupo de mulheres com LES. Métodos : Estudo retrospectivo de 100 pacientes lúpicas para o ICC, variáveis ​​clínicas, epidemiológicas e sorológicas. Resultados : Nenhuma variável epidemiológica interferiu no ICC. Quanto à clínica, pacientes com glomerulonefrite tiveram pior ICC do que os sem (p&lt;0,0001) e os com manifestações de sistema nervoso central tiveram tendência para pior ICC (p=0,09). Portadores de anticorpos anti-Ro (p=0,02) e fator reumatoide (FR; p=0,002) se associaram com ICC menor. Conclusões : A presença de glomerulonefrite se associa com menor sobrevida, e a dos anticorpos anti-Ro e FR com maior sobrevida no LES.

Introduction: Rheumatoid arthritis (RA) is treated with conventional and biological disease-modifying drugs (DMARDs). Objectives: To compare the survival of biological drugs used for the treatment of RA patients. Methods: Retrospective study of medical records of patients who used biological medication for the treatment of RA from January 2020 to January 2022 and this was suspended. Data on the causes of withdrawal, duration of use, epidemiological, clinical and comorbid data were collected. Results: The main reason for discontinuity was failure followed by side effects. Infliximab and adalimumab had the highest survival. BMI (body mass index) and smoking, sex and age did not interfere in this survival. Conclusion: Failure is the most common cause of biological discontinuity. Among the factors studied (smoking, BMI, age and gender) it was not possible to identify a variable that was associated with failure.

Introdução: A artrite reumatoide (AR) é tratada com drogas modificadoras da doença (DMARDs) convencionais e biológicas. Objetivos: Comparar a sobrevida de medicamentos biológicos utilizados para o tratamento de pacientes com AR. Método: Estudo retrospectivo de prontuários de pacientes que utilizaram medicamento biológico para tratamento de AR de janeiro de 2020 a janeiro de 2022 e este foi suspenso. Dados acerca das causas de retirada, tempo de uso, dados epidemiológicos, clínicos e de comorbidades foram coletados. Resultados: O principal motivo da descontinuidade foi a falha seguida por efeitos colaterais. Infliximabe e adalimumabe foram os que apresentaram maior sobrevida. IMC (índice de massa corporal) e o tabagismo, sexo e idade não mostraram interferência nesta sobrevida Conclusão: Falha é a causa mais comum de descontinuidade dos biológicos. Dentre os fatores estudados (fumo, IMC, idade e sexo) não foi possível identificar variável que se associasse com falha.

ABSTRACT Purpose: This study measured fecal calprotectin levels in a series of patients with anterior uveitis in order to determine whether anterior uveitis patients with associated spondyloarthritis have higher levels of fecal calprotectin than patients with anterior uveitis of other etiologies. A third group of patients with spondyloarthritis without uveitis was also evaluated to understand the role of acute anterior uveitis in increasing fecal calprotectin. Methods: In this cross-sectional study, 28 patients were divided into three groups: (a) Group 1, spondyloarthritis and uveitis (n=9); (b) Group 2, spondyloarthritis without uveitis (n=10); and (c) Group 3, uveitis without spondyloarthritis (n=9). The levels of fecal calprotectin were determined. Results: Groups 1 and 2 showed higher median fecal calprotectin levels (101.0 and 93.0 µg/g, respectively) compared with Group 3 (9.0 µg/g) (p=0.02). However, no relationship between fecal calprotectin levels and the presence of uveitis with spondyloarthritis could be demonstrated. Conclusion: Patients with spondyloarthritis with or without acute anterior uveitis have significantly elevated levels of fecal calprotectin. This test may be useful for differentiating spondyloarthrit-associated uveitis from uveitis of other etiologies. Purpose etiologies Methods crosssectional cross sectional groups (a n=9 n9 n 9 (n=9) b (b n=10 n10 10 (n=10) c (c n=9. . determined Results 101.0 1010 101 0 (101. 930 93 93. µgg µg g µg/g respectively 9.0 90 (9. p=0.02. p002 p p=0.02 02 (p=0.02) However demonstrated Conclusion spondyloarthritassociated spondyloarthrit n= (n=9 n=1 n1 (n=10 101. (101 9. (9 p00 p=0.0 (p=0.02 (n= (n=1 (10 ( p0 p=0. (p=0.0 (n (1 p=0 (p=0. p= (p=0 (p= (p

RESUMO Objetivo: Este estudo avaliou os níveis de calprotectina fecal em uma série de pacientes com uveíte anterior na tentativa de determinar se pacientes com uveíte associada com espondiloartrites apresentam níveis mais elevados desta proteína do que pacientes com uveíte anterior de outras etiologias. Um terceiro grupo com espondiloartrites sem uveíte também foi incluído na avaliação para entendimento do papel da uveíte anterior no aumento da calprotectina fecal. Métodos: Estudo transversal de 28 pacientes divididos em três grupos: (a) com espondiloartrites e uveíte (n=9); (b) com espondiloartrites sem uveíte (n=10) e (c) com uveíte sem espondiloartrites (n=9). A dosagem de calprotectina fecal foi avaliada. Resultados: Pacientes com uveíte anterior associada a espondiloartrites apresentaram valores medianos maiores de calprotectina fecal (101 µg/g) que os valores dos pacientes com uveíte sem espondiloartrites (9 µg/g), pacientes com espondiloartrites sem uveíte que também demonstraram valores maiores (93.0 µg/g) que os dos pacientes com uveíte sem espondiloartrites (p=0,02). Conclusão: Pacientes com espondiloartrites com e sem uveíte anterior aguda demonstraram níveis significativamente elevados de calprotectina fecal. Este teste pode ser útil na diferenciação entre uveítes associadas com espondiloartrites de uveítes de outras etiologias. Entretanto, não foi possível demonstrar associação entre o aumento dos níveis de calprotectina fecal e a presença da uveíte em espondiloartrites. Objetivo etiologias Métodos 2 grupos (a n=9 n9 n 9 (n=9) b (b n=10 n10 10 (n=10 c (c n=9. . avaliada Resultados 101 (10 µg/g µgg µg g ( µg/g, , 93.0 930 93 0 (93. p=0,02. p002 p p=0,02 02 (p=0,02) Conclusão Entretanto n= (n=9 n=1 n1 1 (n=1 (1 93. (93 p00 p=0,0 (p=0,02 (n= p0 p=0, (p=0,0 (n p=0 (p=0, p= (p=0 (p= (p